Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefoperazone Sodium

FDA-approved product (injectable, injection), marketed as Cefobid, Cefobid In Plastic Container.

Registered studies
16
Lab records
5
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cefoperazone Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Third-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD12

Repurposing investigation

Cefoperazone Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli94.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

16registered studies name this medicine, for any condition. See them below.

Experimental

  • E. coli: measured active in 1 of 1 lab record
  • K. pneumoniae: measured active in 2 of 4 lab records
Open Cefoperazone Sodium in ChEMBL Registered studies below
Show the 5 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefoperazone Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Hypoalbuminemia on Cefoperazone/Sulbactam Induced Coagulopathy in Post-Operative Surgical Patients

    NCT07773584 · start 2027-04

    Registered record
    Registry ID
    NCT07773584
    Conditions
    Cefoperazone/Sulbactam Induced Coagulopayjy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2027-10
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCefoperazone/Sulbactam Induced Coagulopayjy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients

    NCT07118384 · start 2025-05-01

    Registered record
    Registry ID
    NCT07118384
    Conditions
    Acinetobacter Baumannii Infection
    Interventions
    Cefoperazone-sulbactam injection; Ampicillin - Sulbactam Injection
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-05-01
    Completion
    2026-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinetobacter Baumannii Infection
    InterventionCefoperazone-sulbactam injection; Ampicillin - Sulbactam Injection
    PhaseNot applicable
    Registry statusRecruiting

  • Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment

    NCT07671755 · start 2025-02-01

    Registered record
    Registry ID
    NCT07671755
    Conditions
    Clinical Response; Radiological Response
    Interventions
    colistin plus cefoperazone-sulbactam combination group; Colistin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-02-01
    Completion
    2026-04-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Response; Radiological Response
    Interventioncolistin plus cefoperazone-sulbactam combination group; Colistin
    PhaseNot applicable
    Registry statusCompleted

  • Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application

    NCT06729619 · start 2024-06-03

    Registered record
    Registry ID
    NCT06729619
    Conditions
    Intracranial Infection; Central Infection
    Interventions
    The concentration of anti-infective drugs in blood and cerebrospinal fluid will be determined.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-06-03
    Completion
    2027-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Infection; Central Infection
    InterventionThe concentration of anti-infective drugs in blood and cerebrospinal fluid will be determined.
    PhaseNot recorded
    Registry statusActive not recruiting

  • Prevention of Cefoperazone-induced Coagulopathy

    NCT05742295 · start 2023-02-25

    Registered record
    Registry ID
    NCT05742295
    Conditions
    Antibiotic Side Effect
    Interventions
    Vitamin K
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-02-25
    Completion
    2023-10-05
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Side Effect
    InterventionVitamin K
    PhasePhase 4
    Registry statusCompleted

  • Evaluate Bioequivalence of Burotam (1/1 g/Vial)

    NCT05654090 · start 2022-08-25

    Registered record
    Registry ID
    NCT05654090
    Conditions
    Infectious Diseases
    Interventions
    cefoperazone sodium and sulbactam sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-08-25
    Completion
    2023-02-20
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfectious Diseases
    Interventioncefoperazone sodium and sulbactam sodium
    PhasePhase 4
    Registry statusUnknown

  • Establishment of Risk Factors Model of Drug-induced Coagulation Disorder Caused by Cefoperazone Sulbactam Sodium

    NCT05535309 · start 2021-11-02

    Registered record
    Registry ID
    NCT05535309
    Conditions
    Risk Factors
    Interventions
    cefoperazone sulbactam sodium
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-11-02
    Completion
    2023-12-30
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRisk Factors
    Interventioncefoperazone sulbactam sodium
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Vancomycin Plus Beta-lactams

    NCT03776409 · start 2018-12-12

    Registered record
    Registry ID
    NCT03776409
    Conditions
    Critical Illness
    Interventions
    vancomycin plus piperacillin/tazobactam; vancomycin plus other beta-lactams
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-12-12
    Completion
    2020-05-30
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness
    Interventionvancomycin plus piperacillin/tazobactam; vancomycin plus other beta-lactams
    PhaseNot recorded
    Registry statusCompleted

  • Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.

    NCT03436719 · start 2017-11-06

    Registered record
    Registry ID
    NCT03436719
    Conditions
    Rectal Cancer
    Interventions
    Oral antibiotic; Intravenous antibiotic; Mechanical Bowel Preparation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-11-06
    Completion
    2020-08-31
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Cancer
    InterventionOral antibiotic; Intravenous antibiotic; Mechanical Bowel Preparation
    PhaseNot applicable
    Registry statusUnknown

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline

    NCT02060149 · start 2014-03

    Registered record
    Registry ID
    NCT02060149
    Conditions
    Pneumonia
    Interventions
    C/S plus minocycline.; nebulization with pH 7.4 solution; nebulization with pH 7.8 solution; No nebulization
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2014-03
    Completion
    2015-04
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionC/S plus minocycline.; nebulization with pH 7.4 solution; nebulization with pH 7.8 solution; No nebulization
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis

    NCT01992198 · start 2012-07

    Registered record
    Registry ID
    NCT01992198
    Conditions
    Pancreatitis,Acute Necrotizing
    Interventions
    cefoperazone + metronidazole; oral care by chlorhexidine gluconate; enteral nutrition; Somatostatin; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-07
    Completion
    2016-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatitis,Acute Necrotizing
    Interventioncefoperazone + metronidazole; oral care by chlorhexidine gluconate; enteral nutrition; Somatostatin +1 more
    PhasePhase 4
    Registry statusUnknown

  • Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

    NCT01601093 · start 2011-11

    Registered record
    Registry ID
    NCT01601093
    Conditions
    Respiratory Tract Infections; Urinary Tract Infections
    Interventions
    High dose; Low dose; Cefoperazone and Sulbactam Sodium (CFP/SUB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2011-11
    Completion
    2022-12-15
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Infections; Urinary Tract Infections
    InterventionHigh dose; Low dose; Cefoperazone and Sulbactam Sodium (CFP/SUB)
    PhasePhase 2
    Registry statusSuspended

  • An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia

    NCT01280461 · start 2010-07

    Registered record
    Registry ID
    NCT01280461
    Conditions
    Pneumonia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2010-07
    Completion
    2011-12
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

    NCT00463762 · start 2007-05

    Registered record
    Registry ID
    NCT00463762
    Conditions
    Abscess, Intra-Abdominal; Cholecystitis; Wound Infections; Peritonitis; Appendicitis
    Interventions
    CP-75385-02 Cefoperazone/sulbactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2007-05
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbscess, Intra-Abdominal; Cholecystitis; Wound Infections; Peritonitis +1 more
    InterventionCP-75385-02 Cefoperazone/sulbactam
    PhaseNot recorded
    Registry statusWithdrawn